Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

FDA takeover: Cost to Tylenol maker

By Parija Kavilanz, senior writer


NEW YORK (CNNMoney) -- The government takeover of Johnson & Johnson's Tylenol-making factories is a serious step that could further hurt sales of the company's well-known over-the-counter medicines.

On Thursday, the Food and Drug Administration and the Justice Department announced an agreement with J&J (JNJ, Fortune 500)'s McNeil PPC division that put its plants -- one in Las Piedras, Puerto Rico, one in Fort Washington, Pa., and one in Lancaster, Pa. -- under FDA supervision.

The agreement, known as a consent decree, is a very serious development for J&J.

How serious? Industry watchers said the recalls -- and now the government's intervention -- have dented J&J's reputation and credibility with consumers and its bottom line.

Larry Biegelsen, senior analyst with Wells Fargo Securities, wrote in a note Thursday that he estimates the cost could be in the $50 million to $100 million range during the remediation plan.

That's on top of the $900 million J&J has already lost in sales last year because it yanked drugs off store shelves and hasn't been able to replace them.

McNeil recalled more than 130 million units of Tylenol, Motrin and other OTC drugs for quality concerns and small metal particles in 2010.

Given that the FDA's agreement with J&J could be in place for five years, Biegelsen said the total magnitude of the financial hit on the company's business "is hard to quantify."

Regardless, the hit represents a more serious reputational blow than a financial one. Financially, the impact is a drop in the bucket of J&J's sales last year of $64 billion.

Biegelsen said that while the agreement is an "onerous remediation plan" that could slow down production of McNeil's non-prescription drugs it could also be an opportunity for the company to finally put the recall mess behind it.

With the FDA's supervision, McNeil may be able to fix its problems on a specific timetable.

"The consent decree removes much of the uncertainty regarding next steps for McNeil's recovery plan, without paying any upfront fine," Biegelsen said.

"In our view, it also significantly reduces, but does not eliminate entirely, the risk of a worst-case scenario of plant shut down in Puerto Rico." To top of page

Index Last Change % Change
Dow 18,228.30 133.47 0.74%
Nasdaq 5,305.71 48.22 0.92%
S&P 500 2,159.93 13.83 0.64%
Treasuries 1.56 -0.03 -2.08%
Data as of 10:59pm ET
Company Price Change % Change
Chesapeake Energy Co... 6.23 -0.39 -5.89%
Bank of America Corp... 15.29 0.20 1.33%
Procter & Gamble Co 88.36 0.51 0.58%
Ford Motor Co 11.98 -0.03 -0.25%
Micron Technology In... 18.00 0.64 3.69%
Data as of 4:15pm ET
Sponsors

Sections

Wells Fargo executive Carrie Tolstedt could still walk away from the bank with $77 million in stocks and options, despite new efforts by the bank to curb her controversial pay. More

Despite attacks from Republicans including Donald Trump, the Federal Reserve is a big money maker for U.S. government. More

SpaceX CEO Elon Musk laid out his plan to put humans on Mars to eventually form a self-sustaining colony. More

Low interest rates have pushed some housing markets around the world into bubble-risk territory, according to a new report out of UBS. More